Recruiting

Testing a new injectable treatment for type 2 diabetes

Plain-English translation of NCT07347080 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new medication called Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) to see if it is safe and how your body handles it. The medication uses a relatively new technology to help manage blood sugar in people with type 2 diabetes. This is an early-stage study, which means the treatment has not yet been widely tested in patients.

Current diabetes treatments don't work well enough for everyone, and some people struggle to control their blood sugar even while taking multiple medications. This trial is exploring whether this new medication could offer another option for people whose diabetes isn't well-controlled with their current treatments.

Do you qualify?

You likely qualify if…

you are between 18 and 65 years old
you have been diagnosed with type 2 diabetes for at least 3 months but less than 5 years
your blood sugar levels remain higher than target despite taking metformin (at a dose of at least 1,500 mg per day) with or without another diabetes medication
your body mass index is between 18.5 and 40 kg/m²
you are willing to use contraception and have no plans to become pregnant for at least 3 months after receiving the medication
you are able to understand the trial and willing to follow all study procedures

You likely don't qualify if…

you have type 1 diabetes or diabetes caused by pancreas damage or other conditions
you have had severe diabetes emergencies such as ketoacidosis or hyperosmolar coma within the past 6 months
you have serious diabetes complications such as advanced eye disease, severe nerve damage, or diabetic foot ulcers
you have a history of severe or frequent low blood sugar episodes, or very low blood sugar at screening
you have or have had thyroid cancer, medullary thyroid carcinoma, thyroid nodules, or multiple endocrine neoplasia type 2 in your family

What participation looks like

You would receive a single injection of the medication and then stay in the hospital for at least 7 days so the research team can monitor how you respond to it. During your stay, the doctors will regularly check your blood sugar levels, take blood samples, and watch for any side effects. The study will enroll only 6 to 9 people total, divided into three small groups that will each receive a different dose to determine which dose is safest and best tolerated.

AI-generated summary from trial data · Jun 16, 2026 · Not medical advice

Testing a new injectable treatment for type 2 diabetes

What is this trial?

Do you qualify?

What participation looks like

Trial locations